These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 26476229)

  • 21. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
    Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
    Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost effectiveness of biologic therapies for plaque psoriasis.
    Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
    Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study.
    Lorenzin M; Ortolan A; de Hooge M; Frallonardo P; Piccoli A; Cozzi F; Oliviero F; Punzi L; Ramonda R
    Int J Immunopathol Pharmacol; 2015 Dec; 28(4):479-87. PubMed ID: 26384393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psoriatic arthritis treatment: biological response modifiers.
    Mease PJ; Antoni CE
    Ann Rheum Dis; 2005 Mar; 64 Suppl 2(Suppl 2):ii78-82. PubMed ID: 15708944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and treatment of psoriatic arthritis.
    Mease P; Goffe BS
    J Am Acad Dermatol; 2005 Jan; 52(1):1-19. PubMed ID: 15627075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.
    Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G
    Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
    Chastek B; Fox KM; Watson C; Gandra SR
    Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature.
    Balsa A; Lula S; Marshall L; Szczypa P; Aikman L
    Expert Opin Biol Ther; 2018 May; 18(5):575-584. PubMed ID: 29533116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How early should psoriatic arthritis be treated with a TNF-blocker?
    Harty L; Veale DJ
    Curr Opin Rheumatol; 2010 Jul; 22(4):393-6. PubMed ID: 20520552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
    J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.
    Partsch G; Steiner G; Leeb BF; Dunky A; Bröll H; Smolen JS
    J Rheumatol; 1997 Mar; 24(3):518-23. PubMed ID: 9058659
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rheumatoid arthritis: new developments in biologic therapy.
    Mahajan A; Sharma R; Khajuria R; Bardi GH; Kapoor B; Gupta V
    J Indian Med Assoc; 2006 Jun; 104(6):327-30. PubMed ID: 17058552
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
    Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
    J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging drugs for the treatment of axial and peripheral spondyloarthritis.
    Braun J; Kiltz U; Heldmann F; Baraliakos X
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):1-14. PubMed ID: 25575936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology.
    Salvarani C; Pipitone N; Marchesoni A; Cantini F; Cauli A; Lubrano E; Punzi L; Scarpa R; Spadaro A; Matucci-Cerinic M; Olivieri I;
    Clin Exp Rheumatol; 2011; 29(3 Suppl 66):S28-41. PubMed ID: 21906425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
    Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
    J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness of psoriatic arthritis therapies.
    Gladman DD
    Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics.
    Papoutsaki M; Chimenti MS; Costanzo A; Talamonti M; Zangrilli A; Giunta A; Bianchi L; Chimenti S
    J Am Acad Dermatol; 2007 Aug; 57(2):269-75. PubMed ID: 17574299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.